Literature DB >> 24332689

Unilateral optic disk edema with central retinal artery and vein occlusions as the presenting signs of relapse in acute lymphoblastic leukemia.

R Salazar Méndez1, M Fonollá Gil2.   

Abstract

CLINICAL CASE: A 39-year-old man with Philadelphia chromosome-positive acute lymphoblastic leukemia (LAL Ph+) developed progressive vision loss to no light perception in his right eye. He had optic disk edema and later developed central artery and vein occlusions. Pan-photocoagulation, as well as radiotherapy of the whole brain were performed in several fractions. Unfortunately the patient died of hematological relapse 4 months later. DISCUSSION: Optic nerve infiltration may appear as an isolated sign of a leukemia relapse, even before a hematological relapse occurs. Leukemic optic neuropathy is a critical sign, not only for vision, but also for life, and radiotherapy should be immediately performed before irreversible optic nerve damage occurs.
Copyright © 2013 Sociedad Española de Oftalmología. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Central retinal artery occlusion; Central retinal vein occlusion; Leucemia linfoblástica aguda; Nervio óptico; Obstrucción arteria central retina; Obstrucción vena central retina; Optic nerve; Radioterapia; Radiotherapy

Mesh:

Year:  2013        PMID: 24332689     DOI: 10.1016/j.oftal.2013.10.011

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol        ISSN: 0365-6691


  2 in total

1.  Central retinal vein occlusion as first manifestation of relapse in acute lymphoblastic leukemia.

Authors:  Flávia Kessler Borges; Júlia Biegelmeyer; Samantha Thifani Alrutz Barcelos; Raquel Cristine Breunig
Journal:  Rev Bras Hematol Hemoter       Date:  2015-04-14

2.  Clinical Features of Combined Central Retinal Artery and Vein Occlusion.

Authors:  Hao Wang; Yongye Chang; Fen Zhang; Rong Yang; Suxia Yan; Jieying Dong; Minglian Zhang; Shaomin Peng
Journal:  J Ophthalmol       Date:  2019-10-09       Impact factor: 1.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.